about
Trastuzumab-containing regimens for metastatic breast cancerFat grafting for breast cancer patients: From basic science to clinical studies.Recommendations for the implementation of BRCA testing in the care and treatment pathways of ovarian cancer patients.Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysisGD2 expression in breast cancer.Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations.Rare breast cancer subtypes: histological, molecular, and clinical peculiaritiesDetection of microparticles from human red blood cells by multiparametric flow cytometry.Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials.Prospective Biomarker Analysis of the Randomized CHER-LOB Study Evaluating the Dual Anti-HER2 Treatment With Trastuzumab and Lapatinib Plus Chemotherapy as Neoadjuvant Therapy for HER2-Positive Breast CancerPredictive value of biologic parameters for primary chemotherapy in operable breast cancer.Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective studyProlonged fixed dose rate infusion of gemcitabine with autologous haemopoietic support in advanced pancreatic adenocarcinoma.Activity of first-line epirubicin and paclitaxel in metastatic breast cancer is independent of type of adjuvant therapy.Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter studyLapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer.Timing for starting second-line therapy in recurrent ovarian cancer.Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer.The next generation of biologic agents: therapeutic role in relation to existing therapies in metastatic breast cancer.Relapsed triple-negative breast cancer: challenges and treatment strategies.Maintenance therapy in epithelial ovarian cancer: from chemotherapy to targeted agents.Prognostic impact of proliferation for resected early stage 'pure' invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation.Tumor Stroma Manipulation By MSC.The immune system and hormone-receptor positive breast cancer: Is it really a dead end?Mesenchymal progenitors expressing TRAIL induce apoptosis in sarcomas.18F-Fluoroestradiol Positron Emission Tomography in Breast Cancer Patients: Systematic Review of the Literature & Meta-Analysis.SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab.PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab.Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment?Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study.Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial.High-dose thiotepa and melphalan with hemopoietic progenitor support following induction therapy with epirubicin-paclitaxel-containing regimens in metastatic breast cancer (MBC).Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients.Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial.The clinical relevance of endocrine-therapy-induced changes in lipid metabolism in breast cancer patients.Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management.Letrozole versus letrozole plus Lapatinib (GW572016) in hormone-sensitive, HER2-negative operable breast cancer: a double-blind, randomized, phase II study with biomarker evaluation (EGF109077-LAP107692/LETLOB).Renal safety and efficacy of i.v. bisphosphonates in patients with skeletal metastases treated for up to 10 Years.Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors.
P50
Q24194019-6198FAF7-22CB-46DF-9188-E1355C3D3510Q30249805-EB330FC1-B17A-4CB1-B282-83BF8E13407EQ30250038-6116D02E-C3A0-49F3-814B-225CD46FB263Q30401252-579B89E3-FBB9-4BBC-B627-937E703F4E64Q33761830-1BE98AF8-764A-42FE-BC3E-44FC79DF8A81Q33779181-9B194426-37B8-4E4E-AE81-EB9FD69236E4Q34005143-AF926EC9-C3E0-4B8F-8ABF-415D9C06728CQ35265265-B2863F6E-033B-4292-8038-6F33D4D08C78Q35879081-C434C2C7-DECA-4977-9F77-3C43EA08ADB2Q36064908-FDD5A4A0-25B4-46FE-B1DF-7E32F82BFE16Q36309380-118B00C5-2156-4030-9661-F8F23403E149Q36613992-ECE31917-FB61-489A-A46D-BCA96B638060Q36614865-43854755-3635-4A08-8173-A28F040B3B3FQ36696923-C3E11247-067E-4BD3-B102-C1B88ECAE83EQ37600494-ABC03B7B-CB99-440F-ACA3-040E0DCB470BQ37628693-17FAF788-F9D7-4744-8CE7-B4DB491DA126Q37821896-E7330A91-7273-473E-8F29-9C3497706D23Q37977498-044017A0-38DD-4E85-A9DB-6D3BC781BB9AQ38011294-49BF38AB-12E2-40BF-9BDC-9EC696676A5CQ38120666-4FCC8707-7477-4388-A461-BE536337F8D0Q38222277-E8FCEEA8-160C-4000-B280-9A7957E6B554Q38719132-6B4AB7FA-FAA7-44D1-B0FB-F2A50359CADEQ38764997-5CE68D68-1736-4170-8930-A5115290B336Q38800892-9AA55F33-46F9-4481-AACA-45442D49577AQ38938230-5957221C-A862-4449-B28D-7C6ED62EDB82Q38989266-F10A6D77-F562-43E8-8970-9C13457B8E8AQ39212340-89BD02D2-CBBA-4A72-9E32-2ED37A184F7AQ39767744-F3D989F4-80E9-42ED-8077-10AF3D524976Q40888969-E95777A8-CBC1-48CD-ABBE-563915C6DD7EQ42328025-7433CD4D-C813-4F26-B482-FC40484BD30DQ42497114-5229FC62-6981-49CA-AE3B-E0E0F766BF3EQ43542641-9ED03A3C-8886-41CB-BC00-EC74E6BCA5F9Q44281706-CAE73B6F-2289-418C-935A-81901709D809Q44723581-47DB189A-6F9E-489F-9E13-8D804821E5C7Q45014464-3BEB97B8-259A-459F-8E25-2852BF3E0469Q45925449-A3E4BA23-6ADD-441B-B4E8-527B5427F013Q46466675-5A60FDF2-C489-4C8A-8D9F-1A479366AA9FQ46577618-481B8336-C064-4C2B-A954-8DAD60D2D7C8Q46825019-F4240968-CAE4-4397-BC95-BFB527B3B87DQ46966638-1365247B-D4C2-4270-AAFD-36A145375252
P50
description
researcher, ORCID id # 0000-0002-2375-8397
@en
wetenschapper
@nl
name
Valentina Guarneri
@ast
Valentina Guarneri
@en
Valentina Guarneri
@es
Valentina Guarneri
@nl
type
label
Valentina Guarneri
@ast
Valentina Guarneri
@en
Valentina Guarneri
@es
Valentina Guarneri
@nl
prefLabel
Valentina Guarneri
@ast
Valentina Guarneri
@en
Valentina Guarneri
@es
Valentina Guarneri
@nl
P106
P1153
7801667755
P31
P496
0000-0002-2375-8397